Pfizer reported mid-stage efficacy for tilrekimig (a trispecific antibody targeting IL-4, IL-13 and TSLP) in a Phase 2 trial in moderate-to-severe atopic dermatitis. In the latest disclosed 16-week data, significantly more patients treated with tilrekimig achieved stronger skin clearance than placebo. The company said the highest-dose arms reached a 75% reduction in disease scope and severity versus placebo, and it framed the results as supporting advancement into more advanced testing. Pfizer also referenced plans to evaluate tilrekimig in asthma, chronic obstructive pulmonary disease and further atopic dermatitis development, including head-to-head work against Dupixent. With Dupixent facing a patent cliff starting in 2031, the readout adds another candidate to the crowded IL-4/IL-13 and downstream inflammatory-pathway race.